Iridex Corporation confirmed that Local Coverage Determination (LCD) L37531, relating to Micro-Invasive Glaucoma Surgery (MIGS), became effective on November 17, 2024. This new regulatory framework significantly alters the reimbursement landscape for glaucoma treatments in the United States.
The new LCD explicitly clarifies that treatments performed using Iridex’s laser consoles and probes are not classified as MIGS procedures. Consequently, Iridex’s Cyclo G6® product family remains unaffected by the new reimbursement limitations imposed on MIGS devices.
This regulatory change is expected to increase physician interest and utilization of Iridex’s advanced laser-based treatments for glaucoma, as MIGS procedures now face restrictions on first-line use and stacking. The company currently sells over 50,000 Cyclo G6 probes annually, indicating a substantial installed base that could benefit from this development.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.